<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    LifeBridge 10000, LLC

    LifeBridge 10000, LLC

    LifeBridge 10000, LLC specializes in extending and improving the quality of life f...

    LifeBridge 10000, LLC specializes in extending ...

    Amount Raised:    $23,091.00
    Fundraising Status:    EC
    Filing Type:    CF
    ADiTx Therapeutics, Inc

    ADiTx Therapeutics, Inc

    The discovery of immunosuppressive (anti-rejection) drugs has made possible life-s...

    The discovery of immunosuppressive (anti-reject...

    Filing Type:    RA
    Moderna, Inc.

    Moderna, Inc.

    Moderna is advancing messenger RNA (mRNA) science to create a new class of transfo...

    Moderna is advancing messenger RNA (mRNA) scien...

    Filing Type:    PU
    Cortexyme, Inc.

    Cortexyme, Inc.

    Cortexyme is a biopharmaceutical company developing therapeutics based on data sup...

    Cortexyme is a biopharmaceutical company develo...

    Filing Type:    PU
    Neon Therapeutics, Inc.

    Neon Therapeutics, Inc.

    Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field...

    Neon Therapeutics is a clinical-stage immuno-on...

    Filing Type:    PU
    Nymox Pharmaceutical Corporation

    Nymox Pharmaceutical Corporation

    Nymox Pharmaceutical Corporation specializes in the research and development of th...

    Nymox Pharmaceutical Corporation specializes in...

    Filing Type:    PU
    20/20 GeneSystems, Inc.

    20/20 GeneSystems, Inc.

    20/20 GeneSystems, Inc. an early stage digital diagnostics company with the core m...

    20/20 GeneSystems, Inc. an early stage digital ...

    Fundraising Status:    SASBEC
    Filing Type:    RA
    Veru Inc.

    Veru Inc.

    Our strategy is to be known as “the prostate cancer company”. We aspire to be ...

    Our strategy is to be known as “the prostate ...

    Filing Type:    PU
    FibroGen, Inc

    FibroGen, Inc

    FibroGen, Inc. is a leading science-based biopharmaceutical company discovering an...

    FibroGen, Inc. is a leading science-based bioph...

    Filing Type:    PU
    ©2025 National Investor Network. All Rights Reserved.